Profil pemimpin

Husna Nugrahapraja, Ph.D (Ketua)

Institusi

i. Sekolah Ilmu dan Teknologi Hayati - Institut Teknologi Bandung (SITH-ITB)

ii. Pusat Penelitian Nanosains dan Nanoteknologi Institut Teknologi Bandung (PPNN ITB)

iii. ForMIND Institute

iv. Indonesian Society for Biochemistry and Molecular Biology

v. Indonesian Society for Bioinformatics and Biodiversity

Pendidikan

i. Ph. D -- Scuola Superiore Sant’anna Pisa - Italia (2012-2015)

ii. B. Sc., M. Sc. -- Institut Teknologi Bandung (2004-2011)

Works and Achievements

i. BPPT National Task Force COVID-19 for Non-PCR Diagnostic (2020-now)

Member of Sub-Task Force for Peptides and Aptamer Design

ii. BPPT National Task Force COVID-19 for Whole Genome Sequencing (2020-now)

Member of Sub-Task Force for Bioinformatics Analysis of SARS-CoV2

iii. ASAHI Glass Foundation Grantee (2019-2020)

Principal Investigator for Microbial Metagenomics Project in Banana

Ripening

iv. ForMIND Institute and BioFarma Inc. Grantee (2017)

Principal Investigator for Transcriptomics Landscape Analysis through

NGS Data Analysis

Filemon Jalu Nusantara Putra, M.Eng. (Sekretaris)

Institusi

i. Chemco Prima Mandiri (PT. Prima Kreatif Foodindo)

Research and Development Manager

ii. Ikatan Ilmuwan Indonesia Internasional (i4 Indonesia)

Head of Division

Pendidikan

i. B. Sc. -- Faculty of Sciences, Biology – Universitas Diponegoro

ii. M. Eng. -- Faculty of Engineering, Metabolomics – Osaka University

Acep Riza Wijayadikusumah, Ph.D (Bendahara)

Institusi

i. PT. Bio Farma (Persero)

Researcher – Research and Development Division

Pendidikan

i. B. Sc. – Chemistry, Universitas Padjajaran (2000-2005)

ii. Ph. D – Department of Microbiology and Immunology, University of Melbourne (2012-2017)

Pengalaman Riset

i. Pengembangan vaksin konjugat Haemophilus influenza tipe B cair untuk formulasi vaksin pentavalent yang dikenal sebagai Vaksin Pentabio yang diluncurkan pada 2013

(2007-2009)

ii. Pengembangan vaksin TB baru dengan bekerja sama dengan Lipotek Pty Ltd, Australia

(2009-2012)

iii. Pengembangan sistem deliveri vaksin baru dan pengembangan produk biosimilar

(2012-sekarang)

iv. Pengembangan plasma konvalesen untuk pengobatan COVID-19, serta pengembangan vaksin COVID-19

(2020)